When should continuous veno‑venous hemodialysis (CVVHD) be initiated in a hemodynamically unstable ICU patient with acute kidney injury, and what are the recommended blood flow, dialysate and replacement fluid rates, and anticoagulation strategy?

CVVHD in Hemodynamically Unstable ICU Patients with AKI

In hemodynamically unstable ICU patients with acute kidney injury, continuous veno-venous hemodialysis (CVVHD) or other continuous renal replacement therapy (CRRT) modalities should be initiated when metabolic and fluid demands exceed kidney capacity, prioritizing CRRT over intermittent hemodialysis due to superior hemodynamic stability. 1

Timing of Initiation

Initiate CVVHD emergently when life-threatening complications are present:

• Medically refractory hyperkalemia
• Severe volume overload unresponsive to diuretics
• Severe metabolic acidosis
• Uremic complications (pericarditis, encephalopathy)

2, 1

For patients without immediately life-threatening complications, the decision should be based on the dynamic relationship between metabolic/fluid demands and remaining kidney capacity, rather than single laboratory thresholds alone. 1 Consider initiation when:

• Progressive oliguria (<0.5 mL/kg/h) despite fluid optimization
• Rising catabolism with inability to provide adequate nutrition due to fluid restrictions
• Fluid overload developing despite hemodynamic optimization
• Trend of worsening metabolic parameters (rising creatinine, urea, potassium)

Critical caveat: While earlier initiation (before classic criteria develop) may be associated with improved outcomes in patients receiving CVVHD specifically 3, the optimal timing remains controversial and should integrate clinical judgment about trajectory rather than waiting for absolute thresholds. 1

Modality Selection for Hemodynamic Instability

CRRT (including CVVHD) is strongly preferred over intermittent hemodialysis in hemodynamically unstable patients because it provides:

• Better hemodynamic stability with slower fluid and solute shifts
• Improved tolerance of fluid removal
• Lower risk of intracranial pressure changes
• Continuous metabolic control

4, 1

While RCTs have not demonstrated mortality benefit of CRRT over intermittent modalities, CRRT is more physiologically appropriate for unstable patients. 1 No clear advantage exists between CVVHD and other CRRT modalities (CVVH, CVVHDF). 4

Dosing Parameters

Blood Flow Rate

• Target: 100-150 mL/min 5, 6
• Maintain ≥100 mL/min regardless of systemic blood pressure 6
• Use blood pump to ensure adequate flow independent of patient hemodynamics

Dialysate Flow Rate

• Target: 700-900 mL/hour for standard CVVHD 5
• This translates to approximately 17-22 mL/kg/h for a 70 kg patient

Effluent Volume (Total Clearance)

Deliver 20-25 mL/kg/h of total effluent volume 1, 7

• For a 70 kg patient: 1,400-1,750 mL/hour
• Prescribe higher than target dose as delivered dose typically falls short of prescribed dose 7
• This recommendation is based on high-quality evidence (RENAL and ATN trials) showing no benefit to higher doses 7

Ultrafiltration Rate

• 100-200 mL/hour for fluid removal in overloaded patients 6
• Adjust based on hemodynamic tolerance and fluid balance goals
• Slower rates provide better hemodynamic stability

Anticoagulation Strategy

Regional citrate anticoagulation is the preferred first-line approach for CVVHD when no contraindications exist 2, 1, 7

Citrate Anticoagulation

• Grade 2B recommendation from KDIGO guidelines 2
• Provides superior circuit life and reduced bleeding risk
• Monitor for citrate accumulation (metabolic alkalosis, hypocalcemia with normal ionized calcium)
• Important caveat: Standard citrate solutions provide substantial sodium load (mean 1,754 mmol/day), which can cause excessively rapid sodium correction in hyponatremic patients 8

Alternative Anticoagulation (when citrate contraindicated)

Use unfractionated heparin or low-molecular-weight heparin 2, 7

Contraindications to citrate include:

• Severe liver failure (impaired citrate metabolism)
• Severe lactic acidosis
• Severe shock with tissue hypoperfusion

No Anticoagulation

Consider in patients with:

• Active bleeding
• High bleeding risk
• Heparin-induced thrombocytopenia (if citrate unavailable)

Monitor circuit life and be prepared for more frequent filter changes.

Vascular Access

Use uncuffed non-tunneled dialysis catheter with:

• First choice site: Right internal jugular vein 1
• Second choice: Femoral vein (avoid in high BMI patients) 1
• Third choice: Left internal jugular vein
• Avoid subclavian vein (risk of stenosis) 1
• Use ultrasound guidance for insertion 7
• Confirm placement with chest radiography 7
• Ensure adequate catheter length and gauge to minimize recirculation

Dialysate Composition

Use bicarbonate-containing dialysate rather than lactate-based solutions 7

• Bicarbonate is preferred in shock states
• Standard commercial bicarbonate solutions are widely available
• Lactate-based solutions may cause hyperlactatemia in critically ill patients

Monitoring and Adjustments

Assess delivered dose regularly:

• Actual effluent volume often falls short of prescription 7
• Monitor circuit function and filter life
• Adjust prescription upward if delivered dose inadequate

Metabolic monitoring:

• Electrolytes every 4-6 hours initially (especially potassium, calcium, phosphate, magnesium)
• Acid-base status
• Fluid balance (target net negative in overloaded patients)

Nutritional considerations:

• CVVHD causes loss of 10-15 g amino acids/day plus 5-10 g protein/day 9
• Increase protein provision to compensate (typically 1.5-2.0 g/kg/day)
• Supplement water-soluble vitamins 9

Transition and Discontinuation

Transition from CVVHD to intermittent hemodialysis when:

• Vasopressor support discontinued
• Hemodynamic stability achieved
• Positive fluid balance controllable with intermittent therapy
• Intracranial hypertension resolved (if present)

1

Discontinue RRT when:

• Kidney function recovered (improving urine output, declining creatinine)
• RRT becomes inconsistent with goals of care
• Consider furosemide stress test to assess recovery potential 1

Common Pitfalls

1. Waiting for absolute laboratory thresholds rather than assessing clinical trajectory and demand-capacity mismatch
2. Under-prescribing dose - remember delivered dose is typically less than prescribed
3. Rapid sodium correction in hyponatremic patients receiving citrate anticoagulation 8
4. Inadequate nutritional supplementation to compensate for amino acid/protein losses 9
5. Using intermittent hemodialysis in unstable patients due to familiarity rather than physiologic appropriateness